Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
As for PharmAbcine, this agreement will accommodate more timely and less costly delivery of Olinvacimab for its rapidly expanding list of both clinical and non-clinical studies.
Lead Product(s): Olinvacimab,Pembrolizumab
Therapeutic Area: Oncology Product Name: TTAC-0001
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: PharmAbcine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 02, 2020